Identification of Human Papillomavirus genotypes in juvenile laryngeal papillomatosis. Three-year experience in a concentration hospital in Puebla, Mexico

uvenile laryngeal papillomatosis (JLP) is a chronic benign disease of viral etiology, with an aggressive clinical course. In Mexico, the genotypes of the Human Papilloma Virus (HPV) that cause the disease have been poorly studied. The aim of this study was to identify HPV genotypes in PLJ patients. A descriptive and retrospective study was carried out, the records of patients with PLJ treated in a hospital in Mexico were reviewed, in the period 2018-2021. HPV was identied in all patients for genomes 6, 11, 16, and 18. nine patients were included, 56% women, mean age 9.5 ± 5.7 years; seven patients registered positivity for HPV-11 and 2 for HPV-6. The average age at diagnosis was 2.35 ± 1.77 years, with an average of 12 ± 11.56 surgical procedures. In conclusion, the most frequent genotypes in patients with PLJ were HPV-6 and HPV-11, with the latter predominating

Determinación del genotipo del virus del papiloma humano en pacientes con papilomatosis laríngea juvenil

"La papilomatosis laríngea juvenil es una enfermedad que afecta grupos de todas las edades. Hasta la fecha no se ha demostrado un tratamiento definitivo contra el VPH productor de estas lesiones, aunque se sabe que las lesiones en papilomatosis laríngea usualmente están relacionadas con los genotipos 6 y 11. Sin embargo, en nuestro país sólo se ha realizado un estudio en el que se determinó el genotipo del VPH que afecta a la población con PLJ en el occidente de México, esta patología ha sido pobremente estudiada y descrita en nuestro país y no existen estudios que abarquen nuestra región. A pesar que es una neoplasia benigna, en la población juvenil suele comportarse agresivamente y ciertos subtipos del virus del VPH tienen mayor riesgo de malignización, por lo tanto determinando el genotipo de VPH tendríamos un punto de partida para valorar el pronóstico y la posible aplicación de terapias adyuvantes, que estén justificadas, como la aplicación de la vacuna contra el VPH."

Identificación de genotipos de Virus del Papiloma Humano en papilomatosis laríngea juvenil. Experiencia de 3 años en un hospital de concentración en Puebla, México: Identification of Human Papillomavirus genotypes in juvenile laryngeal papillomatosis. Three-year experience in a concentration hospital in Puebla, Mexico

Background: Juvenile laryngeal papillomatosis (JLP) is a chronic benign disease from viral etiology, whose clinical course can be aggressive. In Mexico, the Human Papillomavirus (HPV) genotypes that cause this disease have been poorly studied. Objective: To identify the HPV genotypes in patients with JLP in a reference Hospital in Puebla, Mexico. Mehods: A retrospective descriptive study was performed in patients with JLP attended in a 3rd level care of the Instituto Mexicano del Seguro Social in Puebla, México, from 2018 to 2021. Medical records were revised. In all patients, HPV identification was performed by polymerase chain reaction for genomes 6, 11, 16 and 18 using specific oligonucleotides. Descriptive statistics were applied. Results: 9 patients were included, 56% women, mean age 9.5 ±5.7 years; 7 patients were HPV-11 positive and 2 HPV-6. The mean age at diagnosis was 2.35 ±1.77 years, with an average of 12 ±11.56 surgical procedures; 5 patients were tracheostomy carriers, 4 had genotype 11; 8 patients were born vaginally, but no patient had maternal genital condylomatous lesions. In the patient born by cesarean section, transmission due to sexual abuse was documented. Conclusions: The most frequent genotypes in patients with JLP in the south-central region of Mexico are HPV-6 and HPV-11, the latter one is predominating.Introducción: La papilomatosis laríngea juvenil (PLJ) es una enfermedad benigna crónica de etiología viral, que tiende a tomar un curso clínico agresivo. En México se han estudiado pobremente los genotipos del Virus del Papiloma Humano (VPH) que causan la enfermedad. Objetivo: Identificar los genotipos del VPH en los pacientes con PLJ en un hospital de concentración en Puebla, México. Métodos: Se realizó un estudio descriptivo y retrospectivo a los pacientes con papilomatosis laríngea juvenil atendidos en un hospital de 3er nivel de atención del Instituto Mexicano del Seguro Social en Puebla, México, en el periodo 2018-2021. Se realizó revisión de expedientes clínicos. En todos los pacientes se identificó el VPH por reacción en cadena de polimerasa para los genomas 6, 11, 16 y 18 utilizando oligonulceótidos específicos. Se aplicó estadística descriptiva. Resultados: Se incluyeron 9 pacientes, 56% mujeres, edad media 9.5 ±5.7 años; 7 pacientes registraron positividad al VPH-11 y 2 al VPH-6. La edad media al diagnóstico fue de 2.35 ±1.77 años, con promedio de procedimientos quirúrgicos de 12 ±11.56; de los 5 pacientes portadores de traqueostomía, 4 fueron positivos a VPH-11; 8 pacientes nacieron por vía vaginal, sin embargo, en ningún caso se reportaron lesiones condilomatosas maternas. En el paciente nacido por cesárea, se documentó transmisión por abuso sexual. Conclusiones: Los genotipos más frecuentes en pacientes con PLJ en la región centro-sur de México son VPH-6 y VPH-11, predominando este último

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective

Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe

Background Little is known about the incidence of severe critical events in children undergoing general anaesthesia in Europe. We aimed to identify the incidence, nature, and outcome of severe critical events in children undergoing anaesthesia, and the associated potential risk factors. Methods The APRICOT study was a prospective observational multicentre cohort study of children from birth to 15 years of age undergoing elective or urgent anaesthesia for diagnostic or surgical procedures. Children were eligible for inclusion during a 2-week period determined prospectively by each centre. There were 261 participating centres across 33 European countries. The primary endpoint was the occurence of perioperative severe critical events requiring immediate intervention. A severe critical event was defined as the occurrence of respiratory, cardiac, allergic, or neurological complications requiring immediate intervention and that led (or could have led) to major disability or death. This study is registered with ClinicalTrials.gov, number NCT01878760. Findings Between April 1, 2014, and Jan 31, 2015, 31â127 anaesthetic procedures in 30â874 children with a mean age of 6·35 years (SD 4·50) were included. The incidence of perioperative severe critical events was 5·2% (95% CI 5·0â5·5) with an incidence of respiratory critical events of 3·1% (2·9â3·3). Cardiovascular instability occurred in 1·9% (1·7â2·1), with an immediate poor outcome in 5·4% (3·7â7·5) of these cases. The all-cause 30-day in-hospital mortality rate was 10 in 10â000. This was independent of type of anaesthesia. Age (relative risk 0·88, 95% CI 0·86â0·90; p<0·0001), medical history, and physical condition (1·60, 1·40â1·82; p<0·0001) were the major risk factors for a serious critical event. Multivariate analysis revealed evidence for the beneficial effect of years of experience of the most senior anaesthesia team member (0·99, 0·981â0·997; p<0·0048 for respiratory critical events, and 0·98, 0·97â0·99; p=0·0039 for cardiovascular critical events), rather than the type of health institution or providers. Interpretation This study highlights a relatively high rate of severe critical events during the anaesthesia management of children for surgical or diagnostic procedures in Europe, and a large variability in the practice of paediatric anaesthesia. These findings are substantial enough to warrant attention from national, regional, and specialist societies to target education of anaesthesiologists and their teams and implement strategies for quality improvement in paediatric anaesthesia. Funding European Society of Anaesthesiology

Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe

Background Little is known about the incidence of severe critical events in children undergoing general anaesthesia in Europe. We aimed to identify the incidence, nature, and outcome of severe critical events in children undergoing anaesthesia, and the associated potential risk factors. Methods The APRICOT study was a prospective observational multicentre cohort study of children from birth to 15 years of age undergoing elective or urgent anaesthesia for diagnostic or surgical procedures. Children were eligible for inclusion during a 2-week period determined prospectively by each centre. There were 261 participating centres across 33 European countries. The primary endpoint was the occurence of perioperative severe critical events requiring immediate intervention. A severe critical event was defined as the occurrence of respiratory, cardiac, allergic, or neurological complications requiring immediate intervention and that led (or could have led) to major disability or death. This study is registered with ClinicalTrials.gov, number NCT01878760. Findings Between April 1, 2014, and Jan 31, 2015, 31 127 anaesthetic procedures in 30 874 children with a mean age of 6.35 years (SD 4.50) were included. The incidence of perioperative severe critical events was 5.2% (95% CI 5.0-5.5) with an incidence of respiratory critical events of 3.1% (2.9-3.3). Cardiovascular instability occurred in 1.9% (1.7-2.1), with an immediate poor outcome in 5.4% (3.7-7.5) of these cases. The all-cause 30-day in-hospital mortality rate was 10 in 10 000. This was independent of type of anaesthesia. Age (relative risk 0.88, 95% CI 0.86-0.90; p<0.0001), medical history, and physical condition (1.60, 1.40-1.82; p<0.0001) were the major risk factors for a serious critical event. Multivariate analysis revealed evidence for the beneficial effect of years of experience of the most senior anaesthesia team member (0.99, 0.981-0.997; p<0.0048 for respiratory critical events, and 0.98, 0.97-0.99; p=0.0039 for cardiovascular critical events), rather than the type of health institution or providers. Interpretation This study highlights a relatively high rate of severe critical events during the anaesthesia management of children for surgical or diagnostic procedures in Europe, and a large variability in the practice of paediatric anaesthesia. These findings are substantial enough to warrant attention from national, regional, and specialist societies to target education of anaesthesiologists and their teams and implement strategies for quality improvement in paediatric anaesthesia